ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2110

Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF)

Torsten Lowin1, Matthias Schneider2 and Georg Pongratz3, 1Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, 2Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Düsseldorf, Germany, 3Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cells, BAFF, belimumab and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: B Cell Biology and Targets in Autoimmune Disease - Poster II: Rheumatoid Arthritis and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  In rheumatoid arthritis (RA), synovial fibroblasts (SF) are one main contributor of joint destruction since they resist apoptosis and secrete pro-inflammatory cytokines and matrix degrading enzymes. Therefore, they are key players in directing immune responses in direct interaction with other cell types, like B cells. TNF superfamily members, like B cell activating factor of the TNF family (BAFF) are important B cell function modulators and survival factors and are produced by synovial fibroblasts under certain conditions. Since better understanding of B cell – fibroblast interaction will lead to potential new treatment targets, we started to characterize this interplay.

Methods:  Osteoarthritis (OA, n=5) and RA (n=5) synovial fibroblasts (SF) were co-cultured in passage 3-6 with B cells. Following a preincubation period of 48h with different inflammatory mediators (TNF, IL-1, IFN-γ) or B cell stimulating factors (BAFF, CpG), B cells were added to SF cultures and incubated for another 48h period. To determine B cell survival, we used AnnexinV/PI costain in FACS. AnnexinV/PI double negative B cells (living) are given as percentage of total B cells. To specifically block the action of BAFF, we used Belimumab.

Results:  The presence of SF increased B cell survival from 5.2% to 55.3% (p<0.001). RA SF as compared to OA SF showed similar capacity to increase B cell survival as compared to OA SF. However, conditioned media from RA SF showed increased capacity to enhance B cell survival as compared to OA SF supernatants (RA: 15.7% vs. OA: 11.1%, p=0.04). SF preincubation with INF-γ (survival 70.8%, p=0.015), IL-1 (survival 71.5%, p=0.018), or CpG (survival 87.7%, p=0.0002) further increased survival of B cells as compared to unstimulated SF. IFN-γ (0.1-50 ng/ml) induced BAFF from SF in a concentration dependent manner (ANOVA p<0.01). RA and OA SF showed the same response to INF-γ. Blocking BAFF by adding Belimumab (10µg/ml) decreased IFN induced survival to control values (survival 52.03%, p=0.58). Belimumab, INF-γ, or IL-1 in B cell only cultures had no effect on survival, respectively. After preincubation of SF with BAFF (0.1-10ng/ml), B cell survival was increased in a concentration dependent manner (ANOVA p<0.01, max. survival 78.7% with BAFF 10ng/ml) and inhibited in the presence of Belimumab (survival 64.9%, p=0.08).

Conclusion:  B cell survival is increased in the presence of RA an OA SF in a similar manner, although RA SF spontaneously produce more soluble B cell survival factors as compared to OA SF. Preincubating fibroblasts with BAFF, IFN-γ, IL-1, or CpG affects fibroblast function to further increase B cell survival. INF-γ- and BAFF-induced SF mediated increase in B cell survival can be blocked by Belimumab. Therefore, strategies to interfere with BAFF directly in the joint might lead to decreased B cell survival and reduced inflammation.


Disclosure: T. Lowin, None; M. Schneider, None; G. Pongratz, None.

To cite this abstract in AMA style:

Lowin T, Schneider M, Pongratz G. Synovial Fibroblasts Regulate B Cell Survival Via B Cell Activating Factor of the TNF Family (BAFF) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/synovial-fibroblasts-regulate-b-cell-survival-via-b-cell-activating-factor-of-the-tnf-family-baff/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-fibroblasts-regulate-b-cell-survival-via-b-cell-activating-factor-of-the-tnf-family-baff/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology